Truxima

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam....

South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...

Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...

South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...

South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...

South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...